Abstract
BackgroundBDB001 is an intravenously administered TLR 7/8 dual agonist immune modulator capable of reprogramming dendritic cells to produce antitumor activities. BDB001 monotherapy has demonstrated favorable tolerability and robust systemic immune...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have